BioLineRx Ltd.

AI-generated fair value estimate for this company.

Method: Net-asset-value approach: $13.1M cash & short-term deposits (as of Jun 30 2026, discounted 5% for near-term operating burn) plus an $11.0M risk-adjusted NPV of pipeline/licensed assets (royalty and milestone potential from the Ayrmid-partnered APHEXDA plus early Phase 1/2a GLIX1 optionality in glioblastoma), divided by ~4.3M ADS (implied by market cap of $11.2M at $2.60/ADS).

Reasoning: BioLineRx is a clinical-stage biopharma with minimal revenue ($1.2M in 2025) and a shrinking cash position, so a standard FCF DCF is not meaningful; net-asset-value plus a modest risk-adjusted pipeline premium is the more defensible approach commonly used for cash-constrained clinical-stage biotechs.